posted on 2023-07-07, 08:59authored byXincheng Yao, Behrouz Ebrahimi, David Le, Mansour Abtahi, ALBERT DADZIE, Jennifer Lim, R.V. Chan
The purpose of this study is to evaluate layer fusion options for deep learning classification of optical coherence tomography (OCT) angiography (OCTA) images. A convolutional neural network (CNN) end-to-end classifier was utilized to classify OCTA images from healthy control subjects, diabetic patients with no retinopathy (NoDR), and non-proliferative diabetic retinopathy (NPDR). For each eye, three en-face OCTA images from the superficial capillary plexus (SCP), deep capillary plexus (DCP), and choriocapillaris (CC) layers were acquired. The performances of the CNN classifier with individual layer inputs and multi-layer fusion architectures, including early-fusion, intermediate-fusion, and late-fusion, were quantitatively compared. For individual layer inputs, the superficial OCTA was observed to have the best performance, with 87.74% accuracy, 80% sensitivity, and 91.08% specificity, to differentiate control, NoDR, and NPDR. For multi-layer fusion options, the best option is the intermediate-fusion architecture, which achieved 93.18% accuracy, 87.45% sensitivity, and 94.55% specificity. To interpret the deep learning performance, the Gradient-weighted Class Activation Mapping (Grad-CAM) was utilized to identify spatial characteristics for OCTA classification. Comparative analysis indicates that the layer data fusion options can affect the performance of deep learning classification, and the intermediate-fusion approach is optimal for OCTA classification of DR.
History
Funder Name
National Eye Institute (R01 EY023522,R01 EY029673,R01 EY030101,R01 EY030842,P30 EY001792); Research to Prevent Blindness
Preprint ID
105932
Highlighter Commentary
Discover the future of diabetic retinopathy (DR) diagnosis with deep learning and OCTA: This study reveals that combining specific retinal layers through intermediate-fusion offers the most accurate DR classification, promising early detection and treatment. #DiabeticRetinopathy #DeepLearning #MedicalResearch
--Mousa Moradi, Ph.D. Candidate in BME, UMASS Amherst